Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Raynauds Disease Treatment Market Heading Into 2029?

In recent years, the market size for the treatment of Raynaud’s disease has seen robust growth. It is projected to expand from a valuation of $1.39 billion in 2024 to $1.49 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.6%. Factors which contributed to the significant growth in the past include heightened awareness about autoimmune disorders, advancements in diagnostic capabilities, broadened application of calcium channel blockers, a rise in the prevalence of connective tissue disorders, and an upswing in the elderly population.

In the upcoming years, the market size for the treatment of Raynaud’s disease is predicted to witness substantial growth, likely reaching $1.98 billion by 2029 with a compound annual growth rate (CAGR) of 7.4%. The forecasted increase over the years can be associated with factors such as the rising usage of telehealth for vascular check-ups, the expansion of tailored medicine, intensified research on endothelial dysfunction, and the soaring incidence due to extreme climates, coupled with the growth in health infrastructure. Some of the key trends shifting the market dynamics in the forecast period include AI integration for early diagnosis and disease tracking, the progress in digital thermal monitoring devices, the creation of targeted biologics, breakthroughs in cell therapy and gene alteration, and the emergence of telemedicine and digital health technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24680&type=smp

Which Factors Are Pushing The Raynauds Disease Treatment Market Forward?

The growth of the raynauds disease treatment market is expected to be driven by an increase in the prevalence of autoimmune diseases. Such conditions occur when the immune system mistakenly attacks healthy tissues of the body, leading to inflammation and damage. This increase is attributed to people living in more sanitized, urban environments that provide less immune system training, coupled with modern lifestyle factors like poor diet, stress, and environmental pollutants. Treatment for Raynaud’s disease helps manage the autoimmune disease by bettering symptom management, reducing tissue damage, and preventing complications resulting from impaired blood flow. For example, a report by the Australia-based governmental organization, the Australian Institute of Health and Welfare in June 2024, mentioned that in 2021-22, hospitalizations due to rheumatoid arthritis were 10,000, a 25% increase from the previous year’s 8,000, coming out to a rate of 39 hospitalizations per 100,000 people. Accordingly, the growing occurrence of autoimmune diseases is propelling the raynauds disease treatment market. The forward momentum of the raynauds disease treatment market is also expected to be driven by increased healthcare spending. This refers to the aggregated sum of money used on medical services, treatments, and health-related resources in a specific timeframe. As the aging population expands, there’s a greater demand for medical services, long-term and age-related care, which places a significant financial strain on healthcare systems and leads to a surge in healthcare expenditure. This increasing expense can improve Raynaud’s disease treatment by facilitating better access to pharmaceuticals, sophisticated diagnostics, specialized care, research for novel therapies, and public awareness initiatives that enable efficient symptom management. For example, according to the American Medical Association, a professional group based in the U.S, in April 2025, U.S. health spending surged by 7.5% in 2023, hitting $4.9 trillion, or $14,570 per person, a marked increase compared to the 4.6% rise noted in 2022. Hence, the escalation in healthcare spending is facilitating the progress of the raynauds disease treatment market.

Which Segment Held The Largest Share In The Raynauds Disease Treatment Market In 2025?

The raynauds disease treatment market covered in this report is segmented –

1) By Treatment Type: Medication, Thermal Therapies, Surgical Procedures, Alteative Therapies

2) By Drug Class: Calcium Channel Blockers, Vasodilators, Antiplatelet Agents

3) By Route of Administration: Oral, Topical, Injectable, Intravenous

4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Pharmacies

Subsegments:

1) By Medication: Calcium Channel Blockers, Alpha Blockers, Vasodilators, Topical Nitrates, Selective Serotonin Reuptake Inhibitors (SSRIs), Phosphodiesterase Inhibitors, Angiotensin Receptor Blockers (ARBs)

2) By Thermal Therapies: Hand Warmers, Thermal Gloves, Heated Pads, Biofeedback-Controlled Thermal Devices

3) By Surgical Procedures: Sympathectomy, Nerve Decompression Surgery, Vascular Surgery

4) By Alternative Therapies: Acupuncture, Biofeedback Therapy, Herbal Remedies, Nutritional Supplements, Stress Management Techniques

How Are Key Trends Driving Expansion In The Raynauds Disease Treatment Industry?

Key players in the Raynaud’s disease treatment sector are heavily focused on developing cutting-edge treatment options, like oral calcium channel blockers, aiming to boost blood circulation by relaxing and expanding blood vessels, which in turn decreases both the occurrence and intensity of vasospastic attacks. Oral calcium channel blockers are a category of medications consumed orally that work in facilitating the relaxation and widening of blood vessels by blocking calcium’s entry to the muscle cells located in the heart and blood vessel walls. For instance, in June 2023, the US-based clinical-stage biopharmaceutical firm, Aisa Pharma Inc., initiated the second half of its RECONNOITER Phase 2b trial, examining Profervia (cilnidipine), an oral calcium channel blocker purposed for treating Raynaud’s syndrome in systemic sclerosis (SSc) patients. This comes after encouraging outcomes from the trial’s initial phase, in which Profervia displayed superior attack frequency and SSc disease severity reduction in comparison to other calcium channel blockers, while also delivering a positive safety track record and good tolerability. The now-progressing trial, armed with a 20 mg dosage, is targeting the significant treatment need for Raynaud’s in SSc, presently a condition devoid of approved treatments.

Which Organizations Are Driving Progress In The Raynauds Disease Treatment Industry?

Major companies operating in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., Concert Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/raynauds-disease-treatment-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Raynauds Disease Treatment Industry?

North America was the largest region in the raynauds disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the raynauds disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24680&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model